Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis.

Ilic I, Sipetic S, Grujicic J, Ilic M.

J Oncol Pharm Pract. 2019 Dec 10:1078155219891631. doi: 10.1177/1078155219891631. [Epub ahead of print] No abstract available.

PMID:
31822198
2.

Necitumumab.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 May 29.

3.

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

Besse B, Barlesi F, Demedts I, Fuentes Pradera J, Robinet G, Gazzah A, Soldatenkova V, Frimodt-Moller B, Kim JS, Vansteenkiste J.

Lung Cancer. 2019 Nov;137:136-143. doi: 10.1016/j.lungcan.2019.09.002. Epub 2019 Sep 3.

PMID:
31586771
4.

A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

Villaruz LC, Cobo M, Syrigos K, Mavroudis D, Zhang W, Kim JS, Socinski MA.

Lung Cancer. 2019 Oct;136:52-56. doi: 10.1016/j.lungcan.2019.08.009. Epub 2019 Aug 14.

PMID:
31445354
5.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

6.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Erratum in: Lung Cancer. 2019 Jun;132:157-158.

7.

Necitumumab for the treatment of advanced non-small-cell lung cancer.

Díaz-Serrano A, Sánchez-Torre A, Paz-Ares L.

Future Oncol. 2019 Mar;15(7):705-716. doi: 10.2217/fon-2018-0594. Epub 2018 Dec 3. Review.

PMID:
30501503
8.

Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.

di Noia V, D'Argento E, Pilotto S, Grizzi G, Caccese M, Iacovelli R, Tortora G, Bria E.

Expert Opin Biol Ther. 2018 Sep;18(9):937-945. doi: 10.1080/14712598.2018.1508445. Epub 2018 Aug 9. Review.

PMID:
30075697
9.

Necitumumab: a new option for first-line treatment of squamous cell lung cancer.

Jiménez Aguilar E, Zugazagoitia Fraile J, Paz-Ares Rodríguez L.

Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):765-772. doi: 10.1080/17425255.2018.1498839. Epub 2018 Jul 31. Review.

PMID:
30025476
10.

Necitumumab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

11.

The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.

Bly CA, Molife C, Brown J, Tawney MK, Carter GC, Cinfio FN, Klein RW.

J Manag Care Spec Pharm. 2018 Jun;24(6):534-543. doi: 10.18553/jmcp.2018.24.6.534.

12.

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.

Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, Grau G, Kurek R, Shepherd FA.

Thromb Res. 2018 Jul;167:50-56. doi: 10.1016/j.thromres.2018.05.004. Epub 2018 May 7.

PMID:
29787943
13.

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance.

Bagchi A, Haidar JN, Eastman SW, Vieth M, Topper M, Iacolina MD, Walker JM, Forest A, Shen Y, Novosiadly RD, Ferguson KM.

Mol Cancer Ther. 2018 Feb;17(2):521-531. doi: 10.1158/1535-7163.MCT-17-0575. Epub 2017 Nov 20.

14.

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

Genova C, Socinski MA, Hozak RR, Mi G, Kurek R, Shahidi J, Paz-Ares L, Thatcher N, Rivard CJ, Varella-Garcia M, Hirsch FR.

J Thorac Oncol. 2018 Feb;13(2):228-236. doi: 10.1016/j.jtho.2017.11.109. Epub 2017 Nov 20.

15.

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.

Ciuleanu T, Socinski MA, Obasaju C, Luft AV, Szczesna A, Szafrański W, Ramlau R, Bálint B, Molinier O, Depenbrock H, Nanda S, Paz-Ares L, Thatcher N.

Clin Lung Cancer. 2018 Mar;19(2):130-138.e2. doi: 10.1016/j.cllc.2017.10.004. Epub 2017 Oct 13.

PMID:
29158123
16.

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

Chigutsa E, Long AJ, Wallin JE.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):560-568. doi: 10.1002/psp4.12209. Epub 2017 Jul 13.

17.

An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.

Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH, Mayo C, Chao GY, Obasaju C, Natale R.

Clin Lung Cancer. 2017 Sep;18(5):480-488. doi: 10.1016/j.cllc.2017.02.002. Epub 2017 Mar 2.

PMID:
28365238
18.

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma.

Thakur MK, Wozniak AJ.

Lung Cancer (Auckl). 2017 Feb 13;8:13-19. doi: 10.2147/LCTT.S104207. eCollection 2017. Review.

19.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.

Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M.

Cancer Res Treat. 2017 Oct;49(4):937-946. doi: 10.4143/crt.2016.423. Epub 2017 Jan 6.

20.

Necitumumab for the treatment of squamous cell non-small cell lung cancer.

Brinkmeyer JK, Moore DC.

J Oncol Pharm Pract. 2018 Jan;24(1):37-41. doi: 10.1177/1078155216682365. Epub 2016 Dec 2. Review.

PMID:
27913776

Supplemental Content

Loading ...
Support Center